The 10 Most Valuable Patents Ever Granted — And What Made Them Worth Billions

Some patents protect inventions. Others protect monopolies. The difference is whether competitors can invent around the claims — or whether the claims are so fundamental that every alternative is either worse or infringing.

Here are 10 patents that created the latter kind of protection, ranked by the revenue and market value they enabled.

1. US5272135 — Lipitor (Atorvastatin)

Assignee: Warner-Lambert (Pfizer) · Revenue: $125B+

The best-selling drug in history. Lipitor's patent covered the specific calcium salt of atorvastatin — a statin that lowered LDL cholesterol more effectively than any competitor. The patent's strength came from covering not just the molecule but the specific crystalline form that made it bioavailable. Generic manufacturers couldn't just make "atorvastatin" — they had to match the exact polymorph, which Pfizer defended aggressively.

2. US6285999 — PageRank

Assignee: Stanford University (licensed to Google) · Value: Enabled Google's entire search monopoly

Not the search engine itself — the ranking algorithm. PageRank modeled the web as a graph where links were votes, and pages with more votes from important pages ranked higher. The patent was so broad it covered essentially any link-analysis-based ranking method. Microsoft and Yahoo spent years trying to develop ranking systems that didn't infringe. By the time they did, Google had won.

3. US6090382 — Humira (Adalimumab)

Assignee: BASF (AbbVie) · Revenue: $20B+/year at peak

The first fully human monoclonal antibody. Unlike earlier antibody drugs derived from mice (which caused immune reactions), Humira was built from human antibody genes. AbbVie extended its exclusivity through a dense thicket of formulation and manufacturing patents — over 100 patents protecting every aspect of production. The result: 20 years without a biosimilar competitor in the US.

4. US4683195 + US4683202 — PCR (Polymerase Chain Reaction)

Assignee: Cetus Corporation · Value: Enabled the entire molecular diagnostics industry

Kary Mullis's invention lets you take a single DNA molecule and make billions of copies. Every COVID test, every genetic screening, every crime-scene DNA analysis depends on PCR. The patents were sold to Roche for $300M — a bargain, given that the global PCR market is now $10B+/year.

5. US5521184 — Gleevec (Imatinib)

Assignee: Ciba-Geigy (Novartis) · Revenue: $4.7B/year at peak

The first drug that targeted a specific cancer-causing protein rather than just killing fast-dividing cells. Gleevec turned chronic myeloid leukemia from a death sentence into a manageable condition. The patent covered the specific tyrosine kinase inhibitor molecule — and because it was the first of its class, there was no obvious alternative chemistry to invent around.

6. US7479949 — Multi-Touch

Assignee: Apple Inc · Value: Defined the smartphone interface

Not "a touchscreen" — those existed for decades. This patent covered the specific gesture-detection system that could distinguish a scroll from a tap from a pinch, using heuristics about finger movement patterns. Every smartphone shipped after 2007 either licensed this approach or spent years developing workarounds.

7. US4237224 — Recombinant DNA (Cohen-Boyer)

Assignee: Stanford University · Value: Enabled the entire biotech industry

The fundamental method for splicing genes into bacteria to produce proteins. Licensed to over 400 companies, generating $255M in royalties for Stanford. Every biologic drug — insulin, growth hormone, monoclonal antibodies — starts with this technique. The patent was deliberately licensed cheaply and non-exclusively to encourage adoption.

8. US8697359 — CRISPR Gene Editing

Assignee: Broad Institute (MIT/Harvard) · Value: Still unfolding — potentially trillions

The method for using Cas9 to edit specific DNA sequences in living cells. The patent battle between Broad and UC Berkeley was the most expensive in biotech history. The winner controls the foundational IP for editing the human genome — with applications in every disease with a genetic component.

9. US9402913 — Sovaldi (Sofosbuvir)

Assignee: Gilead/Pharmasset · Revenue: $10B+ in first year

The first true cure for Hepatitis C — >95% cure rate with a pill, replacing a year of painful interferon injections with ~50% success. Gilead paid $11B for Pharmasset to acquire this patent. They recouped it in 18 months.

10. US8580275 — CAR-T Cell Therapy

Assignee: MSKCC/Juno · Value: Opened a new cancer treatment modality

The method for engineering a patient's own T-cells to recognize and kill cancer cells. Not a drug — a process for reprogramming the immune system. The first CAR-T therapies (Kymriah, Yescarta) cost $373,000–$475,000 per patient — and worked when nothing else did.

The pattern

Every patent on this list shares one trait: the claims covered the mechanism, not the outcome. Lipitor didn't claim "lowering cholesterol" — it claimed the specific molecule. PageRank didn't claim "ranking web pages" — it claimed the specific link-analysis algorithm. Multi-Touch didn't claim "a touchscreen" — it claimed the specific gesture-recognition heuristics.

If your patent application describes what your invention does instead of how it does it, you're writing a marketing document, not a patent.